Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga PSMA-HBED-CC PET in Intermediate to High-Risk Preprostatectomy Patients
NCT03388346Phase 3Completed
- Start
- Feb 2018
- Primary completion
- Jul 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa). Primary endpoints: Sensitivity of Ga 68-labeled PSMA-11 PET/CT for Detection of Regional Pelvic Nodal Metastases at 2 weeks, Specificity of Ga 68-labeled PSMA-11 PET/CT for Detection of Regional Pelvic Nodal Metastases at 2 weeks and 2 more. Started Feb 2018; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03388346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388346.